SUNSHINE TOUR ANTI-DOPING PROGRAM PROHIBITED LIST 2013 SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES PROHIBITED SUBSTANCES
Peptide Hormones, Growth Factors and Related Substances
M1 PROHIBITED SUBSTANCES The use of any drug should be limited to medically justified indications NON-APPROVED SUBSTANCES
Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (i.e. drugs under pre-clinical or clinical development or discontinued, designer drugs, veterinary medicines) is prohibited at all times. S1. ANABOLIC AGENTS
Anabolic Agents are prohibited. 1. Anabolic Androgenic Steroids (AAS)
a. Exogenous1 AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α-androst-1-ene- 3,17-dione); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol;
([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol); dehydrochlormethyltestosterone (4- chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); desoxymethyltestosterone (17α- methyl-5α-androst-2-en-17β-ol); drostanolone; ethylestrenol (19-norpregna-4-en-17α-ol); fluoxymesterone; formebolone; furazabol (17α-methyl[1,2,5]oxadiazolo[3',4':2,3]-5α- androstan-17β-ol); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3- one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α- methylandrosta-1,4-dien-3-one); methandriol; methasterone
dimethyl-5α-androstan-3-one); methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3- one); methyl-1-testosterone
(17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltestosterone; metribolone
17β-hydroxy-17α-methylestra-4,9,11-trien-3-one); mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol
androstane); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α- androst-1-en-3-one); tetrahydrogestrinone
4,9,11-trien-3-one); trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s).
b. Endogenous2 AAS when administered exogenously: androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene-3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); testosterone; and their metabolites and isomers, including but not limited to:
1 Exogenous refers to a substance which is not ordinarily capable of being produced by the body naturally. 2 Endogenous refers to a substance which is capable of being produced by the body naturally
5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane-3β,17α-diol; 5α- androstane-3β,17β-diol; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst- 4-ene-3β,17α-diol; androst-5-ene-3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5- ene-3β,17α-diol; 4-androstenediol
(androst-5-ene-3,17-dione); epi-dihydrotestosterone; epitestosterone; etiocholanolone; 3α-hydroxy-5α-androstan-17-one; 3β-hydroxy-5α-androstan-17-one; 7α-hydroxy-DHEA ; 7β-hydroxy-DHEA ; 7-keto-DHEA; 19-norandrosterone; 19-noretiocholanolone.
Other Anabolic Agents, including but not limited to:
Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol. S2 PEPTIDE HORMONES, GROWTH FACTORS AND RELATED SUBSTANCES
The following substances and their releasing factors are prohibited: 1. Erythropoiesis-Stimulating Agents [e.g. erythropoietin (EPO), darbepoietin (dEPO), hypoxia-inducible factor (HIF) stabilizers, methoxy polyethylene glycol-epoetin beta (CERA), peginesatide (Hematide];
2. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) in males; 3. Corticotrophins: 4. Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1), Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Mechano Growth Factors (MGFs); Platelet- Derived Growth Factor (PDGF); Vascular Endothelial Growth Factor (VEGF) as well as any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching;
and other substances with similar chemical structure or similar biological effects(s).
S3. HORMONE AND METABOLIC MODULATORS The following classes are prohibited: 1. Aromatase inhibitors including, but not limited to, aminoglutethimide, anastrozole, androsta-1,4,6-triene-3,17-dione (androstatrienedione), 4-androstene-3,6,17 trione (6-oxo) exemestane, formestane, letrozole, testolactone. Selective Estrogen Receptor Modulators (SERMs) including, but not limited to, raloxifene, tamoxifen, toremifene Other anti-estrogenic substances including, but not limited to, clomiphene, cyclofenil, fulvestrant. Agents modifying myostatin function(s) including, but not limited to, myostatin inhibitors. Metabolic modulators: Insulins and Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists (e.g. GW 1516), PPARδ-AMP-activated protein kinase (AMPK) axis agonists (e.g.AICAR) S4. DIURETICS AND OTHER MASKING AGENTS Masking agents are prohibited. They include: Diuretics3, desmopressin, plasma expanders (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol), probenecid, and other substances with similar biological effect(s). Local application of felypressin in dental anaesthesia is not prohibited. Diuretics include: Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene, and other substances with a similar chemical structure or similar biological effect(s) (except drosperinone, pamabrom and topical dorzolamine and brinzolamide, which are not prohibited). The use of any quantity of a substance subject to the threshold limits (i.e. formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or other masking agent requires the deliverance of a specific Therapeutic Use Exemption for that substance in addition to the one granted for the diuretic or other masking agent. S5. BETA BLOCKERS The entire class of Beta Blockers is prohibited, including but not limited to the following: Acebutolol, alprenolol, atenolol, bendroflumethiazide, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol. S6. STIMULANTS All stimulants (including both optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included on the 2013 SUNSHINE TOUR Monitoring List4. Stimulants include: a: Non-Specified Stimulants: Adrafinil; amfepramone; amiphenazole; amphetamine; amphetaminil; benfluorex; benzphetamine; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; dimethylamphetamine; etilamphetamine; famprofazone; fencamine; fenetylline; fenfluramine; fenproporex; furfenorex; mefenorex; mephentermine; mesocarb; methamphetamine(d-); p-methylamphetamine; methylenedioxyamphetamine; methylenedioxymethamphetamine; modafinil; norfenfluramine; phendimetrazine; phenmetrazine; phentermine; 4-phenylpiracetam (carphedon); prenylamine; prolintane. A stimulant not expressly listed in this section is a Specified Substance.
4 The following substances included on the 2013 SUNSHINE TOUR Monitoring List: (bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradol, synephrine) are not considered Prohibited Substances.
b: Specified Stimulants (examples): Adrenaline**; cathine***; ephedrine****; etamivan; etilefrine; fenbutrazate; fencamfamin; heptaminol; isometheptene; levmetamfetamine; meclofenoxate; methylephedrine****; methylhexaneamine (dimethylpentylamine); methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine (methylsynephrine); parahydroxyamphetamine; pemoline; pentetrazol; phenpromethamine; propylhexedrine; pseudoephedrine*****; selegiline; sibutramine; strychnine; tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s). ** Local administration (e.g. nasal, ophthalmologic) of Adrenaline or co-administration with local anaesthetic agents is not prohibited. *** Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter. **** Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter. ***** Pseudoephedrine is prohibited when its concentration in urine is greater than 150 micrograms per milliliter. S7. NARCOTICS
The following narcotics are prohibited: Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine.
The presence of hydrocodone, morphine/codeine ratio; tramadol will be monitored in order to detect patterns of misuse in golf. S8. CANNABINOIDS
Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9-tetrahydrocannabinol (THC) and cannabimimetics (e.g.”Spice”, JWH018, JWH073, HU-210) are prohibited. S9. GLUCOCORTICOSTEROIDS
All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes. Their use requires a Therapeutic Use Exemption Application and approval. Topical
iontophoresis/phonophoresis), gingival, nasal, ophthalmic and perianal disorders are not prohibited. Intraarticular, periarticular, peritendinous, epidural, intradermal injections and inhalation routes are notprohibited. S10. BETA-2 AGONISTS
All beta-2 agonists (including both optical isomers where relevant) are prohibited except inhaled salbutamol (maximum 1600 micrograms over 24 hours), inhaled formoterol (maximum 54 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with manufacturers’ recommended therapeutic regime.
The presence of salbutamol in urine in excess of 1000ng/ml or formoterol in excess of 40ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding unless the Player proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of a therapeutic dose up to the maximum indicated above. Terbutaline when administered by inhalation, requires a Therapeutic Use Exemption application. A TUE application should be submitted and a Medical File prepared and submitted on request when a TUE is required, for example to explain an Adverse Analytical Finding.
PROHIBITED METHODS MANIPULATION OF BLOOD AND BLOOD COMPONENTS The following are prohibited: 1.
The administration or reintroduction of any quantity of autologous, homologous or heterologous blood or red blood cell products of any origin into the circulatory system.
Artificially enhancing the uptake, transport or delivery of oxygen, including but not limited to perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products, excluding supplemental oxygen.
Any form of intravascular manipulation of the blood or blood components by physical or chemical means.
CHEMICAL AND PHYSICAL MANIPULATION The following are prohibited: 1. Tampering, or Attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Control is prohibited. These include but are not limited to urine substitution and/or adulteration (e.g. proteases).
Intravenous infusions and/or injections of more than 50 mL per 6 hour period are prohibited except for those legitimately received in the course of hospital admissions or clinical investigations.
M3. GENE DOPING The following, with the potential to enhance sport performance, are prohibited: 1.
The transfer of polymers of nucleic acids or nucleic acid analogues;
The use of normal or genetically modified cells;
To achieve the dream skin you always wanted, you have to be committed to yourself, and ZBodySculpt & Medical Spa is dedicated to help you every step of the way. Sunspots are discolorations of the skin that appear on areas of the body repeatedly exposed to the sun, usual y in people over the age of 40. Although they are a sign of sun damage, they aren't dangerous. They do, however, give away a
SUGÁRTERÁPIÁS ÉS ONKOLÓGIAI SZAKMAI KOLLÉGIUM TITKÁR: PROF. DR. KÁSLER DR.SZŰCS MIKLÓS ORSZÁGOS ONKOLÓGIAI INTÉZET BÁCS-KISKUN 1122 BUDAPEST, RÁTH GYÖRGY U. 7-9. ONKORADIOLÓGIAI KÖZPONT TEL.: 224 8686, 224 8600 6000 KECSKEMÉT, NYÍRI ÚT 38. 0FAX.: 224 8687, 224 8620 TEL.:06-76-516-762 06-76-481-840 Javaslat az onkológiai l